Core Viewpoint - Meizhong Jiahe (02453) has received approval for its subsidiary, Guangzhou Taihe Oncology Hospital, to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its competitive advantage in the oncology field [2][4]. Group 1: Company Developments - Meizhong Jiahe's stock price increased by 8.67%, reaching HKD 2.13, with a trading volume of HKD 664,600 [2][4]. - The approval allows the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [2][4]. - This qualification positions the company as a specialized oncology medical institution with the capability to introduce innovative drugs and devices, thereby broadening its business scope and creating a differentiated competitive advantage in the market [2][4]. Group 2: Industry Context - The "Hong Kong-Macao Drug and Medical Device Access" initiative is a key implementation measure of the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [2][4]. - The initiative aims to facilitate the use of clinically necessary drugs and advanced medical devices in designated institutions within the Greater Bay Area, enhancing healthcare access for patients [2][4].
美中嘉和现涨近9% 子公司广州泰和肿瘤医院获批进入“港澳药械通”指定医疗机构名单